<?xml version='1.0' encoding='utf-8'?>
<Document xmlns="urn:iso:std:iso:20022:tech:xsd:pacs.002.001.10"><FIToFIPmtStsRpt><GrpHdr><MsgId>PACS002-ACSC-14e46da9</MsgId><CreDtTm>2025-09-22T10:00:00+00:00Z</CreDtTm></GrpHdr><OrgnlGrpInfAndSts><OrgnlMsgId>PAIN-2025-09-22-Northern_Pharma_BV-7f9ecf40</OrgnlMsgId><OrgnlMsgNmId>pain.001.001.09</OrgnlMsgNmId><GrpSts>PART</GrpSts></OrgnlGrpInfAndSts><OrgnlPmtInfAndSts><OrgnlPmtInfId>PMTINF-2025-09-22-259ecc</OrgnlPmtInfId><TxInfAndSts><StsId>STS-1466466e</StsId><OrgnlInstrId>INST-20250922-00007</OrgnlInstrId><OrgnlEndToEndId>E2E-20250922-00007</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-22T10:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="CHF">13693.16</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts><TxInfAndSts><StsId>STS-94c5bd06</StsId><OrgnlInstrId>INST-20250922-00056</OrgnlInstrId><OrgnlEndToEndId>E2E-20250922-00056</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-22T10:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="CAD">9430.04</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts><TxInfAndSts><StsId>STS-4a65121f</StsId><OrgnlInstrId>INST-20250922-00070</OrgnlInstrId><OrgnlEndToEndId>E2E-20250922-00070</OrgnlEndToEndId><TxSts>ACSC</TxSts><AccptncDtTm>2025-09-22T10:00:00+00:00Z</AccptncDtTm><OrgnlTxRef><Amt><InstdAmt Ccy="GBP">12126.27</InstdAmt></Amt></OrgnlTxRef></TxInfAndSts></OrgnlPmtInfAndSts></FIToFIPmtStsRpt></Document>